Hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤临床分析

Hyper-CVAD/MA regimen in the treatment of relapsed or refractory non-Hodgkin's lymphoma

目的:评价hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤的疗效、安全性和不良反应。方法:24例复发或难治性非霍奇金淋巴瘤患者采用hyper-CVAD/MA方案治疗。化疗每28天循环1个周期,下一周期治疗前评价疗效,每周评价不良反应。结果:24例患者中,总有效率为75%,其中CR 11例(45.83%),PR 7例(29.17%),1例(4.1%)患者因疾病进展死亡。1年无进展生存(PFS)率为50.11%,1年总生存(OS)率为79.8%。不良反应主要为化疗相关的血液学不良反应,均可耐受。结论:hyper-CVAD/MA方案治疗复发或难治性非霍奇金淋巴瘤,近期疗效满意,治疗相关不良反应易于控制,值得临床推广。

Objective：To evaluate the safety and efficacy of hyper-CVAD/MA regimen in the treatment for relapsed or refractory non-Hodgkin＇s lymphoma.Methods： All 24 patients with relapsed or refractory non-Hodgkin＇s lymphoma were treated by hyper-CVAD/MA regimen.Results： The overall response rate of 24 cases of patients was 75%,including 11 cases（45.83%） complete response,7 cases（29.17%） patial response,1（4.1%） patient died of disease progression.One-year progression-free survival（PFS） was 50.11%,one-year overall survival rate was 79.8%.Adverse reactions mainly including chemotherapy-related hematologic toxicity and could be tolerated.Conclusion： The hyper-CVAD/MA regimen has a satisfying short-term therapeutic effect on patients with relapsed or refractory non-Hodgkin＇s lymphoma,the side effects coulol be controled.